Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Lipidio Pharmaceuticals logo — A Unique Approach to Treating Obesity

Lipidio Pharmaceuticals

A Unique Approach to Treating Obesity

Founded 2020 United States San Diego, United States 5 employees Series A Total: $20.00M Biopharma, Biotechnology +1

General Information

Company Name Lipidio Pharmaceuticals
Founded Year 2020
Location United States San Diego, United States
Founders / Decision Makers
Team member
Employees 5
Industries Biopharma, Biotechnology, Health Care
Funding Stage Series A
Business Model B2B, B2D
Revenue Model Licensing, Product Sales
Social

BounceWatch is an independent company data service, not affiliated with Lipidio Pharmaceuticals. To contact Lipidio Pharmaceuticals, visit lipidiopharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Lipidio Pharmaceuticals compare?

A PDF of Lipidio Pharmaceuticals and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Lipidio Pharmaceuticals soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Lipidio Pharmaceuticals

Lipidio Pharmaceuticals, founded in 2020 and headquartered in San Diego, CA, is a biotech startup focusing on leveraging drug development expertise to innovate in treating obesity and sebaceous hyperplasia. Their approach, encapsulated in the slogan "A Unique Approach to Treating Obesity," involves acquiring molecules with untapped therapeutic potential and optimizing their development for market success or strategic exit.

Operating within the Biopharma, Biotechnology, and Health Care industries, Lipidio recently secured a $20.00M Series A investment on 10 November 2022. Notable investors include industry leaders John Maraganore and Nancy T. Chang, signaling strong confidence in Lipidio's potential to deliver transformative health solutions. Their strategic focus and expert team position them as a compelling entity for further investment in a market seeking innovative solutions for critical health challenges.

Taxonomy: obesity treatment, drug development, molecule transformation, therapeutic potential, clinical development, marketing approval, therapeutics for obesity, sebaceous hyperplasia treatment, non-alcoholic steatohepatitis, Prader-Willi syndrome, antipsychotic drug-induced weight gain, metabolic disease, dermatology, pharmaceuticals

Services & Products

Development of obesity treatment drugs
Research on skin signaling mechanisms
Synthesis and secretion of hormones

Target Customers

Healthcare providers Pharmaceutical companies Obesity treatment centers Medical researchers

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $20.00M 2
John Maraganore, Nancy T. Chang
10 Nov 2022
Series A Undisclosed 3
3E Bioventures Capital
3E Bioventures Capital, Alethea Capital Management +1
03 Mar 2020

Lipidio Pharmaceuticals Alternatives & Competitors

View All Alternatives
Lipidio Pharmaceuticals vs
Sciwind Biosciences
Sciwind Biosciences

Pioneering treatments to empower physicians in addressing metabolic disorders with advanced protein...

Series C
1 employees
Biotechnology, Health Care
Lipidio Pharmaceuticals vs
Response Pharmaceuticals
Response Pharmaceuticals

A Clinical Stage (Phase 2) biopharmaceutical company developing treatments for weight management and...

9 employees
Biopharma, Biotechnology
Lipidio Pharmaceuticals vs
Atom Therapeutics
Atom Therapeutics China

Atom Therapeutics Co., Ltd

Series D
4 employees
Biotechnology, Health Care
View all alternatives

FAQ About Lipidio Pharmaceuticals

A Unique Approach to Treating Obesity
Lipidio Pharmaceuticals was founded in 2020.
Lipidio Pharmaceuticals is headquartered in San Diego, United States.
Lipidio Pharmaceuticals operates in Biopharma, Biotechnology and Health Care. Its work centres on obesity treatment, drug development, molecule transformation and therapeutic potential. Its customers include Healthcare providers, Pharmaceutical companies and Obesity treatment centers.
Lipidio Pharmaceuticals has a B2B and B2D business model. Its revenue comes from Licensing and Product Sales.
Lipidio Pharmaceuticals has approximately 5 employees.
Lipidio Pharmaceuticals has completed 2 funding rounds, raising a total of $20.00M. The latest funding stage is Series A.
Lipidio Pharmaceuticals offers: Development of obesity treatment drugs, Research on skin signaling mechanisms, Synthesis and secretion of hormones.
Top alternatives and competitors to Lipidio Pharmaceuticals include Sciwind Biosciences, Response Pharmaceuticals, Atom Therapeutics, Cirius Therapeutics, Resalis Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Lipidio Pharmaceuticals and Sciwind Biosciences are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Lipidio Pharmaceuticals, https://bouncewatch.com/company/lipidio-pharmaceuticals, updated 11 March 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes